Spinocerebellar ataxia 7 (SCA7) is a neurodegenerative disorder characterized by degeneration of the cerebellum, brainstem and retina. The gene responsible for SCA7, located on chromosome 3p, recently was cloned and shown to contain a CAG repeat in the coding region of the gene, that is expanded in SCA7 patients of French origin. We examined the SCA7 repeat region in four Swedish SCA7 families as well as in 57 healthy controls. All Swedish SCA7 patients exhibited expanded CAG repeats with a strong negative correlation between repeat size and age of onset. The repeat length in SCA7 patients ranged from 40 to >200 repeats. The largest expansion was observed in a juvenile case with an age of onset of 3 months, and represents the longest polyglutamine stretch ever reported. In patients with 59 repeats or more, visual impairment was the most common initial symptom observed, while ataxia predominates in patients with <59 repeats. Two of the Swedish SCA7 families analysed in this study were shown to be related genealogically. The other two SCA7 families could not be traced back to a common ancestor. All four families shared the same allele on the disease chromosome at a locus closely linked to SCA7, suggesting the possibility of a founder effect in the Swedish population.
SCA7 is a neurodegenerative disorder that belongs to the clinically and genetically heterogeneous group of autosomal dominant cerebellar ataxias, ADCAs. The ADCAs have been subdivided into three groups denoted ADCA types I-III. SCA7 belongs to the ADCA type II subtype where the ataxia is associated with retinal degeneration. ADCA type II seems to be genetically very homogeneous, and in all ADCA type II families analysed the gene responsible has been localized to the same region on chromosome 3p, regardless of ethnic background (1-3). The gene for spinocerebellar ataxia (SCA) 7 recently was cloned and shown to contain a (CAG)n repeat in the coding region of the gene that is expanded in SCA7 patients (4). To date, eight disorders caused by expanded CAG repeats have been identified and include, besides SCA7, four other ADCAs: SCA1, 2, 3 and 6, as well as spinal and bulbar muscular atrophy (SBMA), Huntington's disease (HD) and dentatorubral pallidoluysian atrophy (DRPLA) (5-15). The function of the genes responsible for these disorders are in most cases unknown, and there are no significant sequence homologies between the different genes outside of the CAG repeat region. The subcellular localization of the genes also differs and for SCA7 has been shown to be nuclear. The mechanism underlying the polyglutamine disorders is not known, but a common dominant gain of function, causing neuron- and disease-specific cell death, has been proposed.
All the CAG disorders identified so far have been shown to be associated with genetic anticipation, where an earlier age of onset and a more severe progression of the disease is observed in successive generations. The age of onset has, in all cases, been shown to be correlated negatively with the size of the (CAG)n expansion, and the anticipation seen is due to the tendency of the repeats to expand during parent to child transmission (5-15). In all these disorders except SCA6, the threshold for the pathological allele is similar and of the order of 37-40 CAG repeats.
Here we describe the expansion of the SCA7 CAG repeat region in patients from four Swedish ADCA type II families and the effect of the repeat length on the clinical manifestation.
The SCA7 CAG repeat region was amplified in 16 diagnosed patients from four Swedish ADCA type II families as well as from three asymptomatic individuals known to carry the disease haplotype (1) and compared with healthy relatives and 57 unrelated healthy controls.
The control individuals showed allele sizes ranging from seven to 15 repeats. Ten CAG repeats was the most common allele observed, constituting 63% of the alleles in the normal population (Fig. 1), and 34 individuals (60%) were heterozygous at the SCA7 repeat locus.
Figure
Figure In this study, we have analysed the SCA7 CAG repeat region in four Swedish SCA7 families and in 57 neurologically unaffected controls. The study reveals a highly polymorphic CAG expansion on the disease chromosome of all SCA7 patients tested, in contrast to a relatively stable normal allele in all unaffected family members and healthy controls. The 10 CAG allele represents 60% of the alleles in the normal Swedish population and less instability is observed in the SCA7 locus of the normal population than has been observed for most other polyglutamine disorders (5,13-14,16-17). All Swedish SCA7 patients and three asymptomatic individuals with the disease haplotype were shown to carry CAG expansions with great variability in repeat size on their disease chromosomes. The repeat size varied from 40 to >200 repeats. The size difference between the normal and mutated repeat range is as much as 28 repeats in the Swedish population, and no intermediate alleles were observed. The largest SCA7 expansion (>200 repeats) exceeds the largest expansion reported so far, including a juvenile case of HD with 180 repeats (18).
Our data show a strong negative correlation between the number of CAG repeats and the age at onset and disease severity, including death. SCA7 has been reported to show a more pronounced anticipation when paternally transmitted (4). This is less obvious in the Swedish SCA7 families, where one paternal transmission resulted in an unchanged repeat size and in two paternal transmissions small contractions were observed (44-40 and 42 repeats respectively). These three individuals are still asymptomatic but, assuming a linear correlation between CAG repeat size and age at onset of disease, the carriers have an expected age at onset of 42-47 years and are likely to develop the disease in the near future. However, the most extreme anticipation observed, from 51 to >200 repeats, is also paternally transmitted. The fact that the CAG repeat in this case has expanded to more than four times its original size from one generation to the next suggests high repeat instability during spermatogenesis.
The cardinal symptoms of SCA7, cerebellar ataxia and visual impairment, were present in all but one case, BIII:21, who has no decrease in visual acuity 13 years after onset of the disease although the retina shows slight pigmentary mottling of the type seen in SCA7. Visual impairment was the initial symptom in all patients but one (A V:5) with >= 59 repeats. Patient A V:5 started with ataxia 2 years before visual impairment was noted; however, at the same time as ataxia developed, a slight supranuclear ophthalmoplegia for ascending vertical movements was observed.
Even if the onset of overt ataxia could be defined in all cases, several patients reported a history of clumsiness or a feeling of clumsiness since childhood although they were able to participate in ordinary physical school activities. Thus, `subclinical' impairment of coordination due to the disease process may precede clinical onset of SCA7.
By genealogical studies, we have been able to show that two of the four families analysed in this study have a common ancestor that dates back to the mid-17th century. This is 5-8 generations before the appearance of any individual with documented symptoms of SCA7 and suggests that a pre-mutation exists in these families. It is possible that an increase over the observed, relatively stable, range of normal alleles (7-15 repeats) makes the locus more unstable and the carriers at risk for afurther increase in the repeat to a pathological size. Alternatively, they may carry a polymorphism or mutation outside of the CAG repeat region that predisposes this allele to further expansion,as has been proposed for Machado-Joseph disease in which an intragenic CGG/GGG polymorphism 3' of the CAG repeat seems to effect the stability of the repeat (19,20). The haplotypes carrying a CGG on the expanded allele and a GGG on the normal allele were reported to show significantly larger repeat instability than individuals homozygous for either the CGG or the GGG polymorphism, suggesting an inter-allelic interaction involved in the repeat instability (19).
Previous reports have mapped the SCA7 locus to the 12 cM region between markers D3S1300 and D3S1285 by recombinations (21) and, more recently, to a 5 cM region between markers D3S1600 and D3S3635 on yeast artificial chromosomes (YACs) (4). Taken together with these data, our haplotype data suggests that all Swedish SCA7 patients may indeed have a common ancestor, as they all share the same allele for the marker D3S1287 (immediately flanked by D31600 and D3S3635) on their disease chromosomes. Since it might be difficult genealogically to establish kinship further back than that which has already been done in these families, a polymorphism within or immediately next to the SCA7 gene that enables linkage disequilibrium studies would be needed to test this hypothesis.
This study presents clinical information on 20 SCA7 patients from four Swedish ADCA type II families, families A-D. The study includes DNA from 16 affected patients as well as three at-risk carriers with the disease haplotype (1) and 34 healthy siblings of affected individuals or non-affected spouses/parents. Family A is a five generation kindred previously described, descending from a couple born in the late-19th century in the province of Västerbotten in the northern part of Sweden (22). Family B descends from the same geographical area as family A, while families C and D both originate from different parts of the province of Dalarna in the middle part of Sweden. Diagnosis of SCA7 as well as non-carrier state was ascertained by clinical examination by a neurologist (L.F.) and an ophthalmologist (O.S.) in 12 of the patients and two of the at-risk carriers. The clinical diagnosis in the remaining eight cases (including five deceased patients) was based on information from medical records which included assessments by neurologists or neuropaediatricians. All cases had a family history compatible with autosomal dominant inheritance, with at least two family members in different generations with progressive cerebellar ataxia and pigmentary retinopathy which caused visual impairment in all but one case. The patients age at onset of ataxia, visual impairment and dysarthria are difficult to evaluate in many cases with SCA7 where the impairment has a gradual onset and progression. We defined the age at onset of a symptom as the age at which the patient (from direct interview or from available medical records) first had noticed the symptom, irrespective of whether medical contact was made or not at that time.
The normal range of CAG repeats was examined by analysis of 57 neurologically healthy individuals from northern Sweden.
DNA was extracted from peripheral blood, histopathological material and cell lines by standard procedures (23). The repeat region was amplified by PCR using primers 4U1024 (5'-TGTTACATTGTAGGAGCGGAA-3') and 4U716 (5'-CACGACTGTCCCAGCATCACTT-3') (4). One primer was end-labelled using [[gamma]-32P]dATP (Amersham, 3000 Ci/mM) and T4 polynucleotide kinase. Amplifications were performed in 5 µl reactions using 0.2 mM end-labelled and unlabelled primer respectively, 1* buffer for Taq polymerase (Boehringer Mannheim), 0.1 mM dNTP, 10% dimethylsulfoxide and 0.1 U of Taq polymerase (Boehringer Mannheim). Cycling conditions were as follows: 95°C for 4 min, 57°C for 1 min, 72°C for 1 min (1 cycle), 95°C for 1 min, 57°C for 1 min, 72°C for 1 min (35 cycles) and finally 95°C for 1 min, 57°C for 1 min, 72°C for 5 min (1 cycle). Five µl of formamide dye mix were added to the samples before denaturing at 95°C for 4 min. Two µl of the product was separated on a 6% polyacrylamide-urea gel. Fragments were detected by autoradiography.
Polymorphic microsatellite regions were amplified by PCR using primer pairs from the Genethon map (24), obtained from the Nordic Microsatellite Marker Bank, Uppsala, Sweden, or from Research Genetics. The primers were end-labelled with [[gamma]32P]dATP (Amersham, 3000 Ci/mM) using polynucleotide kinase, subjected to PCR amplification and analysed as previously described (25).
We are most grateful to the families for participating in this study. We also wish to thank Eleonora Westermark for technical assistance, Michael Daws for careful reading of the manuscript and Nacer Abbas and Gilles David for sharing data prior to publication. This study was supported by grants from the Swedish Medical Research Council (Project No. 09745), the County Council of Västerbotten, the Swedish Association of Neurologically Disabled and by Torsten och Ragnar Söderbergs Stiftelser.
Human Molecular Genetics Pages
Introduction
Results
Analysis of the SCA7 CAG repeat region in Swedish ADCA type II patients and healthy controls
Correlation between CAG repeat length and clinical manifestation
Haplotype analysis and genealogical investigations
Discussion
Materials And Methods
Family and control material
Analysis of SCA7 (CAG)n repeat region
Haplotype analysis
Acknowledgements
References
![]()
REFERENCES
This page is run by Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, as part of the OUP Journals
Comments and feedback: www-admin{at}oup.co.uk
Last modification: 6 Jan 1998
Copyright© Oxford University Press, 1998.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
K. Suzuki, M. Katsuno, H. Banno, Y. Takeuchi, N. Atsuta, M. Ito, H. Watanabe, F. Yamashita, N. Hori, T. Nakamura, et al. CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA Brain, January 1, 2008; 131(1): 229 - 239. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Cagnoli, G. Stevanin, C. Michielotto, G. Gerbino Promis, A. Brussino, P. Pappi, A. Durr, E. Dragone, M. Viemont, C. Gellera, et al. Large Pathogenic Expansions in the SCA2 and SCA7 Genes Can Be Detected by Fluorescent Repeat-Primed Polymerase Chain Reaction Assay J. Mol. Diagn., February 1, 2006; 8(1): 128 - 132. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Bowman, S.-Y. Yoo, N. P. Dantuma, and H. Y. Zoghbi Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation Hum. Mol. Genet., March 1, 2005; 14(5): 679 - 691. [Abstract] [Full Text] [PDF] |
||||
![]() |
O Y Bang, P H Lee, S Y Kim, H J Kim, and K Huh Pontine atrophy precedes cerebellar degeneration in spinocerebellar ataxia 7: MRI-based volumetric analysis J. Neurol. Neurosurg. Psychiatry, October 1, 2004; 75(10): 1452 - 1456. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Brusco, C. Gellera, C. Cagnoli, A. Saluto, A. Castucci, C. Michielotto, V. Fetoni, C. Mariotti, N. Migone, S. Di Donato, et al. Molecular Genetics of Hereditary Spinocerebellar Ataxia: Mutation Analysis of Spinocerebellar Ataxia Genes and CAG/CTG Repeat Expansion Detection in 225 Italian Families Arch Neurol, May 1, 2004; 61(5): 727 - 733. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Y. Bang, K. Huh, P. H. Lee, and H. J. Kim Clinical and Neuroradiological Features of Patients With Spinocerebellar Ataxias From Korean Kindreds Arch Neurol, November 1, 2003; 60(11): 1566 - 1574. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. O. Dorschner, D. Barden, and K. Stephens Diagnosis of Five Spinocerebellar Ataxia Disorders by Multiplex Amplification and Capillary Electrophoresis J. Mol. Diagn., May 1, 2002; 4(2): 108 - 113. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Cancel, C. Duyckaerts, M. Holmberg, C. Zander, G. Yvert, A.-S. Lebre, M. Ruberg, B. Faucheux, Y. Agid, E. Hirsch, et al. Distribution of ataxin-7 in normal human brain and retina Brain, December 1, 2000; 123(12): 2519 - 2530. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Gu, Y. Wang, X. Liu, B. Zhou, Y. Zhou, and G. Wang Molecular and Clinical Study of Spinocerebellar Ataxia Type 7 in Chinese Kindreds Arch Neurol, October 1, 2000; 57(10): 1513 - 1518. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Abe, T. Tsuda, M. Yoshida, Y. Wada, T. Kano, Y. Itoyama, and M. Tamai Macular Degeneration Associated With Aberrant Expansion of Trinucleotide Repeat of the SCA7 Gene in 2 Japanese Families Arch Ophthalmol, October 1, 2000; 118(10): 1415 - 1421. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yanagisawa, M. Bundo, T. Miyashita, Y. Okamura-Oho, K. Tadokoro, K. Tokunaga, and M. Yamada Protein binding of a DRPLA family through arginine-glutamic acid dipeptide repeats is enhanced by extended polyglutamine Hum. Mol. Genet., May 22, 2000; 9(9): 1433 - 1442. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||






